Autophagy inhibition using hydrochloroquine in breast cancer patients: a pilot study - HCQ TRIA
- Conditions
- proven invasive adenocarcinoma of the breast
- Registration Number
- EUCTR2010-022842-26-NL
- Lead Sponsor
- niversity Medical Centre Nijmegen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 20
•Patients with core-biopsy proven invasive adenocarcinoma of the breast
•Any tumor with a size = 1cm (NOT inflammatory breast cancer)
•WHO-performance score 0 or 1
•Written informed consent
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
•Any psychological, familial, sociological or geographical condition potentially hampering adequate informed consent or compliance with the study protocol
•Hampered liver or kidney function
•Serious gastro-intestinal disease
•Neurological disease (including epilepsy)
•Hematological disease
•Psoriasis
•Porphyry
•G6PD deficiency
•Hypersensitivity for quinine
•Use of gold containing drugs, oxyfenbutazone, fenylbutazone, digoxin
•Operation for breast cancer foreseen within 14 days after inclusion in the study.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method